Combined virustatic antimediator (COVAM) treatment of common colds

A method of treating the common cold and related disorders selected from the group consisting of sinusitis, otitis, influenza, infectious exacerbations of chronic obstructive pulmonary disease, comprising the steps of:

• administering to a patient in need thereof a therapuetically effective amount of at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses;
• and
• administering to said patient a therapeutically effective amount of at least two antiinflammatory compounds specific for at least two different inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathway, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, the kinin pathway, and the pathway used by exogenous opioid agonists, at least one of said two antiinflammatory compounds being capable of reducing the volume of mucus secretion in the sinus cavity or reducing the viscosity of mucus in the sinus cavity, said steps of administering said antiviral agent and said two antiinflammatory compounds being performed simultaneously and achieving a synergistic result in the treatment of the common cold.

A kit for combatting the common cold and related disorders selected from the group consisting of sinusitis, otitis, influenza, and infectious exacerbations of chronic obstructive pulmonary disease, comprising:

• at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses;
• and
• at least one antiinflammatory compound which reduces the volume of mucus secretion in the sinus cavity or reduces the viscosity of mucus in the sinus cavity.

A kit for combatting the common cold and related disorders selected from the group consisting of sinusitis, otitis, influenza, and infectious exacerbations of chronic obstructive pulmonary disease, comprising:

• at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses;
• and
• at least two antiinflammatory compounds specific for at least two different inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathways, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, and the kinin pathway, at least one of said two different antiinflammatory compounds being capable of reducing the volume of mucus secretion in the sinus cavity or reducing the viscosity of mucus in the sinus cavity.